Vaishali Pharma Limited

NSE VAISHALI.NS

Vaishali Pharma Limited EBITDA Margin for the year ending March 31, 2024: 3.68%

Vaishali Pharma Limited EBITDA Margin is 3.68% for the year ending March 31, 2024, a -77.46% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Vaishali Pharma Limited EBITDA Margin for the year ending March 31, 2023 was 16.31%, a 34.95% change year over year.
Vaishali Pharma Limited EBITDA Margin for the year ending March 31, 2022 was 12.08%, a 42.28% change year over year.
Vaishali Pharma Limited EBITDA Margin for the year ending March 31, 2021 was 8.49%, a 65.40% change year over year.
Vaishali Pharma Limited EBITDA Margin for the year ending March 31, 2020 was 5.13%, a -7.92% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NSE: VAISHALI.NS

Vaishali Pharma Limited

CEO	Mr. Hemanth Damodar Pathak
IPO Date	Aug. 22, 2017
Location	India
Headquarters	706 to 709, Aravalli Business Center
Employees	27
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care Pet Food Plastics

Description

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The company also provides formulation products, such as antibiotics/antibacterial, anti-platelet, laxative, anti-ulcer/enzyme, anti-asthmatic, anti-malarial, anti-cold/anti-allergic/anti-viral, anti-psychotic, anti-fungal, anti-inflammatory/analgesic/anti-pyretic, anti-diabetic, cardiac, vitamins, topical steroids/corticosteroids, and other formulations. In addition, it offers veterinary pharmaceutical, nutraceutical, oncology, herbal, and surgical products. The company was founded in 1989 and is headquartered in Mumbai, India.

Key trends

Past 5 years